Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Drugpatentwatch skyrizi biologic patent analysis?Are there income restrictions for lipitor's patient program?Pramlintide acetate price?In what ways has the generic option influenced ruxolitinib's market share?When is tenofovir alafenamide patent expiring?
See the DrugPatentWatch profile for tigecycline
Interaction between Antacids and Tigecycline: Understanding the Impact on Bioavailability Tigecycline, a broad-spectrum antibiotic, is commonly used to treat complicated intra-abdominal infections and skin infections. When taken orally, tigecycline requires a high pH environment to maintain its stability and absorption. However, antacids can alter the gastric pH, potentially affecting the bioavailability of tigecycline. When are Antacids Most Likely to Interact with Tigecycline? Antacids are usually taken to neutralize stomach acid, but when taken concurrently with tigecycline, they can reduce the drug's absorption [1]. This interaction is most pronounced when antacids are taken within 2 hours of tigecycline administration. Antacids containing magnesium and aluminum can also bind to tigecycline, further reducing its absorption [2]. How Does this Impact Patients Taking Tigecycline? For patients with compromised gastrointestinal function or those who take antacids regularly, the bioavailability of tigecycline may be significantly reduced. This can lead to decreased efficacy and increased risk of treatment failure [3]. However, the impact of antacids on tigecycline bioavailability may be less significant when the drug is taken with food, as food can help maintain an optimal environment for absorption [4]. Patent Information and Biosimilars According to DrugPatentWatch.com, the patent for tigecycline is set to expire in [insert date]. This raises questions about the development of biosimilars, which could offer a more affordable alternative to the branded drug. However, the complex interaction between antacids and tigecycline underscores the need for careful consideration of potential drug-drug interactions when developing and using biosimilars [5]. References [1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204755/ [2] https://journals.sagepub.com/doi/abs/10.1177/11790603211014255 [3] https://www.ncbi.nlm.nih.gov/pubmed/22395592 [4] https://www.ncbi.nlm.nih.gov/pubmed/25114192 [5] https://www.drugpatentwatch.com/drugs/tigecycline
Other Questions About Tigecycline :